2217 ⎘
Animals characterised by purpose; Animal model, e.g. for test or diseases; Animal model for genetic diseases Animal model for autoimmune diseases
GENE THERAPY
#2COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#3COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#4TRANSGENIC MOUSE MODELS OF HUMAN ADAPTIVE AND INNATE IMMUNITY AND METHODS OF USE
#5REGULATION OF IMMUNE RESPONSES THROUGH SELECTIVE NEURAL ACTIVATION
#6COMPOSITION
#7MICRORNA INHIBITOR THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
#8GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES
#9Novel Animal Model for Autoimmune Disease
#10NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE
#11Methods of Treating Rheumatoid Arthritis Using RNA-Guided Genome Editing of HLA Gene
#12COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#13Composition for inducing proliferation or accumulation of regulatory T cells
#14METHOD OF DETERMINING TOXICITY OF AN IMMUNOMODULATORY DRUG FOR USE IN HUMANS
#15GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN
#16Method of determining toxicity of an immunomodulatory drug for use in humans preliminary class
#17MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENT
#18METHOD FOR CONSTRUCTING MODEL OF VITILIGO AND THE USE OF THE MODEL
#19GENETICALLY MODIFIED NON-HUMAN ANIMAL EXPRESSING A B2M/FCRN FUSION PROTEIN
#20Method for integrating biological tissues with a vascular system
#21COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#22A GENETIC MOUSE MODEL OF AUTOIMMUNE ADVERSE EVENTS AND IMMUNE CHECKPOINT BLOCKADE THERAPY
#23GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES
#24METHOD OF DETERMINING TOXICITY OF AN IMMUNOMODULATORY DRUG FOR USE IN HUMANS
#25Mouse having a humanized B-cell activating factor gene
#26GRAVES' OPHTHALMOPATHY PHENOTYPE ANIMAL MODEL, CONSTRUCTION METHOD THEREFOR, AND METHOD FOR SCREENING THERAPEUTIC MATERIAL FOR GRAVES' OPHTHALMOPATHY
#27VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#28Method of determining toxicity of an immunomodulatory drug for use in humans
#29Genetically modified non-human animal with human or chimeric IL15
#30MicroRNA inhibitor therapy in systemic lupus erythematosus
#31Composition for inducing proliferation or accumulation of regulatory T cells
#32Methods of treating rheumatoid arthritis using RNA-guided genome editing of HLA gene
#33METHODS AND COMPOSITIONS FOR MODULATING INNATE LYMPHOID CELL PATHOGENIC EFFECTORS
#34Composition for inducing proliferation or accumulation of regulatory T cells
#35Composition for inducing proliferation or accumulation of regulatory T cells
#36Transgenic mice expressing human TREM proteins and methods of use thereof
#37Non-human animals having a humanized B-cell activating factor gene
#38Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
#39Non-invasive in vivo imaging and methods for treating diabetes
#40Composition for inducing proliferation or accumulation of regulatory T cells
#41Composition for inducing proliferation or accumulation of regulatory T cells
#42TRANSGENIC ANIMALS EXPRESSING MUTANT TREX1 PROTEIN USEFUL AS A MODEL OF AUTOIMMUNE DISEASE
#43HUMANIZED MOUSE MODEL OF MYASTHENIA GRAVIS AND MSC THERAPY
#44Mode of inducing renal transplant rejection on animals and its manufacturing approach
#45Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
#46Thyroid stimulating hormone receptor peptides and uses thereof
#47Non-human animal having human CD3 gene substituted for endogenous CD3 gene
#48Composition for inducing proliferation or accumulation of regulatory T cells
#49Method of treating vitiligo using mutant HSP70i
#50Method for treating arthritis using IK factor or nucleic acid encoding IK factor
#51Non-human animals having a humanized B-cell activating factor gene
#52DNA methyltransferases for the treatment and prevention of arthritis
#53Composition for inducing proliferation or accumulation of regulatory T cells
#54Non-invasive in vivo imaging and methods for treating type I diabetes
#55Animal model and method for studying gene-gene interactions
#56Composition for inducing proliferation or accumulation of regulatory T cells
#57Composition for inducing proliferation or accumulation of regulatory T cells
#58Prophylactic and/or therapeutic agent for inflammatory disease, and method for screening prophylactic and/or therapeutic drug for inflammatory disease
#59NON HUMAN ANIMAL MODEL FOR ULCERATIVE COLITIS AND ITS MAIN COMPLICATIONS
#60Method for treating arthritis using IK factor or nucleic acid encoding IK factor
#61Composition for inducing proliferation or accumulation of regulatory T cells
#62Non-human animals having a humanized B-cell activating factor gene
#63NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE
#64COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#65Non-invasive in vivo imaging and methods for treating type I diabetes
#66Non human animal model for ulcerative colitis and its main complications
#67Soluble protein CD5 or CD6 for the treatment of cancer or tumor or for use as an adjuvant
#68Biomarkers associated with autoimmune diseases of the lung
#69Immunoadjuvant composition and use thereof
#70METHODS AND COMPOSITIONS FOR TREATMENT
#71Human CTLA-4 antibodies and their uses
#72Conjugates comprising mannan and myelin oligodentrocyte glycoprotein (MOG)
#73TRIPLE TRANSGENIC MOUSE MODEL OF AUTOIMMUNE DISEASE AND NF-KAPPA B IN VIVO IMAGING
#74DNA vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus
#75Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease
#76Method for manufacturing animal model for researching pulmonary tumor and use thereof
#77Animal models for demyelination disorders
#78DRAK2 EXPRESSION IS ASSOCIATED WITH DIABETES
#79Nonhuman model animal lacking the ability to control lymphocyte migration
#80Method of treatment of diabestes or reduction in pancreatic beta-cells
#81Endodermal progenitor cells
#82Reduction of graft-versus-host disease by modulation of SHIP activity
#83VACCINE PREVENTING AND/OR TREATING AUTOIMMUNE DISEASES
#84PIG MODEL FOR PSORIASIS
#85Models of thrombotic thrombocytopenic purpura and methods of use thereof
#86Human CTLA-4 antibodies and their uses
#87Manipulation of Regulatory T Cell and Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists
#88Tl1a in treatment of disease
#89Method For Inducing Beta Cell Neogenesis From Epithelial Cells
#90SGRF gene-modified mouse
#91Transgenic Pig with Diabetes and Method for Producing the Same
#92Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
#93BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
#94Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes
#95Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer
#96Mouse Models of Crohn's Disease and a Method to Develop Specific Therapeutics
#97Nonhuman model animal lacking the ability to control lymphocyte migration
#98Nonhuman model animal lacking the ability to control lymphocyte migration
#99Compositions and methods for treatment of autoimmune and related diseases
#100CBG gene as a genetic marker of hypercortisolism and associated pathologies
#101DNA vaccination for treatment of autoimmune disease
#102Animal models for demyelination disorders
#103Control of NK cell function and survival by modulation of SHIP activity
#104Prevention of primary sjogren' s Syndrome by ICA69 deficiency
#105Nonhuman model animal of Th2-mediated hyperimmune response
#106Method of Suppressing Cancer
#107Knockout Non-Human Animal
#108Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of SOCS sequence in the animal
#109Animal model for identifying agents that inhibit or enhance CTLA4 signaling
#110Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
#111Pancreatic progenitor cells and methods for isolating the same
#112Assay
#113Method of treatment and prophylaxis
#114Use of calcium binding proteins to improve cardiac contractile function
#115Goodpasture's syndrome model mouse
#116Model of autoimmune disease and methods for identifying agents against autoimmune disease
#117Animal models for demyelination disorders
#118Cathepsin G (CTSG) Disruptions, Compositions and Methods Relating Thereto
#119Compositions and methods for treatment of autoimmune and related diseases
#120Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
#121Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
#122Transgenic mice containing SOCS-5 cytokine signalling suppressor gene disruptions
#123Mouse model for autoimmune disorders
#124Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes
#125Immunologically privileged cells and uses thereof
#126Modulation of type IIß phosphoinositide phosphate kinase
#127DNA vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus
#128Prevention of primary Sjogren's Syndrome by ICA69 deficiency
#129Transgenic mouse expressing human FcRn protein
#130Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
#131Nucleic acids encoding truncated soluble tumor necrosis factor
#132BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
#133Cloning of rhadinovirus genome and methods for its use
#134Human CTLA-4 antibodies and their uses
#135Ghrelin-carrier conjugates
#136FcγRIIa transgenic animal model for autoimmune disease
#137Animal model for identifying agents that inhibit or enhance CTLA4 signaling
#138Compositions and methods for the treatment and diagnosis of immune disorders
#139Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens
#140Nonhuman model animal of Th2-mediated hyperimmune response
#141P2x7 receptor-deficient non-human animals and uses thereof
#142Nonhuman model animal lacking the ability to control lymphocyte migration
#143Non-human animal model of systemic lupus erythematosus
#144Sgrf gene-modified non-human animals
#145Non-human mammal model of autoimmune disease having OX40L gene transferred thereinto
#146Transgenic mice expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor